Zimmer Biomet Reports Strong Fourth Quarter and Full Year 2025 Financial Performance Zimmer Biomet showcases impressive financial growth with a 10.9% increase in Q4 sales. The company also announces plans for future growth and shareholder returns.

Zimmer Biomet Reports Strong Fourth Quarter and Full Year 2025 Financial Performance #USA #financial_results #Warsaw #Zimmer_Biomet #ZBH

Investigating Zimmer Biomet: Shareholder Concerns Over Revenue Discrepancies and Market Strategies Amid Crisis Hagens Berman is looking into Zimmer Biomet Holdings following significant investor concerns after drastic revenue projections were missed.

Investigating Zimmer Biomet: Shareholder Concerns Over Revenue Discrepancies and Market Strategies Amid Crisis #USA #San_Francisco #Zimmer_Biomet #Hagens_Berman #ZBH

Zimmer Biomet Receives U.S. FDA Clearance for Enhanced Version of ROSA® Knee Robotic Technology Zimmer Biomet (NYSE: ZBH) announced U.S. FDA 510(k) clearance of ROSA® Knee with OptimiZe™, an enhanced version of its ROSA Knee robotic system for total knee replacement surgery.The update adds five OptimiZe features—Planning, Landmarking, Tracking, Kinematic Alignment and Experience—plus integration with ZBEdge® Analytics. The company said OptimiZe Planning™ can reduce planning time by an average of 46%. Zimmer Biomet plans a targeted release later in 2025 and expects U.S. commercial availability in Q1 2026.

#ZBH Zimmer Biomet Receives U.S. FDA Clearance for Enhanced Version of ROSA® Knee Robotic Technology

www.stocktitan.net/news/ZBH/zimmer-biomet-r...

Zimmer Biomet Announces Third Quarter 2025 Financial Results Zimmer Biomet (NYSE: ZBH) reported third quarter 2025 results on November 5, 2025: net sales $2.001B, up 9.7% reported, 8.6% on a constant currency basis and 5.0% on an organic constant currency basis. Net earnings $230.9M and adjusted diluted EPS $1.90 (+9.2%). The company completed the acquisition of Monogram Technologies and closed the April Paragon 28 acquisition, expanding robotics and extremities portfolios. Japan PMDA approval was received for the iodine-treated iTaperloc Complete and iG7 Hip System. Full-year 2025 reported revenue and adjusted EPS guidance are maintained while constant-currency revenue ranges were narrowed.

#ZBH Zimmer Biomet Announces Third Quarter 2025 Financial Results

www.stocktitan.net/news/ZBH/zimmer-biomet-a...

Zimmer Biomet Announces FDA Breakthrough Designation for World's First Iodine-Treated Total Hip Replacement System Zimmer Biomet (NYSE: ZBH) announced the FDA granted Breakthrough Device Designation for its iodine-treated total hip replacement system on October 28, 2025. This is the first time the company has received this designation. The system integrates controlled-release Iodine Technology into the iTaperloc Complete and iG7 Hip System to help address periprosthetic joint infections (PJI). The device received PMDA approval in Japan in September 2025 as the world’s first approved orthopedic implant with this iodine treatment. The FDA program offers prioritized review and earlier agency interaction during regulatory review.

#ZBH Zimmer Biomet Announces FDA Breakthrough Designation for World's First Iodine-Treated Total Hip Replacement System

www.stocktitan.net/news/ZBH/zimmer-biomet-a...

Zimmer Biomet Earnings: Revenue Surges 7% to $2.1B, Acquires AI Robotics Firm as Growth Accelerates Q2 sales reach $2.1B with 7% growth, EPS rises to $2.07. Company raises full-year outlook and announces strategic AI robotics acquisition. Get full details.

#MGRM #ZBH Zimmer Biomet Announces Second Quarter 2025 Financial Results

www.stocktitan.net/news/MGRM/zimmer-biomet-...

Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions Zimmer Biomet (NYSE: ZBH) has announced a definitive agreement to acquire Monogram Technologies (NASDAQ: MGRM) for an upfront payment of $4.04 per share, representing an equity value of approximately $177 million. The deal includes a CVR worth up to $12.37 per share tied to development milestones through 2030.The acquisition will expand Zimmer Biomet's ROSA® Robotics platform with Monogram's semi- and fully autonomous robotic technologies. Monogram's FDA-cleared CT-based, semi-autonomous AI-navigated total knee arthroplasty technology is expected to be commercialized with Zimmer Biomet implants in early 2027. The deal positions Zimmer Biomet to potentially become the first company to offer fully autonomous surgical robots in orthopedics.The transaction is expected to be neutral to adjusted EPS in 2025-2027 and accretive thereafter, with revenue growth contribution beginning in 2027. The deal is anticipated to close later in 2025, subject to regulatory and shareholder approvals.

#MGRM #ZBH Zimmer Biomet Announces Definitive Agreement to Acquire Monogram Technologies, Expanding Robotics Suite with Autonomous Solutions

www.stocktitan.net/news/MGRM/zimmer-biomet-...

Breaking News: ( NYSE: #ZBH ) (ZBH) Technical Data

Zimmer Biomet Earnings Reveal Strategic Wins: $1.9B Revenue, Paragon 28 Deal Drives Growth Outlook Q1 revenue hits $1.9B with strong hip portfolio growth. Discover updated 2025 guidance following Paragon 28 acquisition and new product launches. See full results.

#ZBH Zimmer Biomet Announces First Quarter 2025 Financial Results

www.stocktitan.net/news/ZBH/zimmer-biomet-a...

Zimmer Biomet Enhances Shareholder Value with New Dividend Announcement for Q1 2025 Zimmer Biomet Holdings, Inc. has declared a quarterly cash dividend of $0.24 per share for Q1 2025, providing consistent returns to shareholders.

Zimmer Biomet Enhances Shareholder Value with New Dividend Announcement for Q1 2025 #USA #dividends #Warsaw #Zimmer_Biomet #ZBH

Zimmer Biomet Earnings Surge Past $2B Mark as Major Foot & Ankle Market Entry Looms Zimmer Biomet delivers 4.3% sales growth in Q4, reaching $2.023B, while announcing strategic Paragon 28 acquisition to penetrate the $5B foot and ankle market. Key FDA approvals boost portfolio.

#FNA #ZBH Zimmer Biomet Announces Fourth Quarter and Full-Year 2024 Financial Results

www.stocktitan.net/news/FNA/zimmer-biomet-a...

Major Healthcare Shakeup: Zimmer Biomet's $1.1B Move Targets $5B Foot Surgery Market Zimmer Biomet strengthens its position in the $5B foot and ankle segment with Paragon 28 acquisition, adding high-growth surgical solutions and targeting 18% revenue growth in 2024.

#FNA #ZBH Zimmer Biomet Announces Definitive Agreement to Acquire Paragon 28

www.stocktitan.net/news/FNA/zimmer-biomet-a...

2/2 Tickers: #AMZN #AXP #BA #COF #DFS #GOOGL #GPN #IP #MA #MRK #NKE #SWKS #TM #ULTA #V #WMT #ZBH
#PersonalFinance #Barrons
ybbpersonalfinance.proboards.com/thread/757/b...

#ZBH Zimmer Biomet Receives FDA Approval for Oxford® Cementless Partial Knee, Only Cementless Partial Knee Replacement Implant in the U.S.

www.stocktitan.net/news/ZBH/zimmer-biomet-r...

#ZBH Zimmer Biomet to Present at Citi's 2024 Global Healthcare Conference

www.stocktitan.net/news/ZBH/zimmer-biomet-t...

#ZBH Zimmer Biomet Announces CE Mark Certification for Persona® Revision Knee System

www.stocktitan.net/news/ZBH/zimmer-biomet-a...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#IBRX, #ZBH, #QSR, #VIST, #HLF

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected!

PM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #CPRI 9.2x
2. #IBRX 6.8x
3. #ZBH 4.1x
4. #RUN 3.3x
5. #QSR 3.2x

#OptionFlow #OptionsTrading #Trading